

**Pharmacological Effects of Exogenous NAD on Mitochondrial Bioenergetics, DNA Repair  
and Apoptosis**

Maria Pittelli, Roberta Felici, Vanessa Pitozzi, Lisa Giovannelli, Elisabetta Bigagli, Francesca

Cialdai, Giovanni Romano, Flavio Moroni and Alberto Chiarugi

*Department of Preclinical and Clinical Pharmacology (M.P., R.F., V.P., L.G., E.B., F.M., A.C.) and*

*\*Laser Center for Medical Application-CEO (F.C., G.R.), University of Florence, Florence, Italy*

**Running title:** Exogenous NAD and cytoprotection

**Author for Correspondence:**

Maria Pittelli PhD

Department of Preclinical and Clinical Pharmacology

Viale Pieraccini 6

University of Florence

50139 Florence

Italy

maria.pittelli@unifi.it

**Number of text pages:** 28

**Number of Figures:** 6

**Number of References:** 48

**Number of words in:**

**Abstract:** 225

**Introduction:** 711

**Discussion:** 1330

**List of Abbreviations:** NAD, Nicotinamide adenine dinucleotide; PARP-1, poly(ADP-ribose) polymerase-1; PAR, poly(ADP-ribose); iNAD, intracellular NAD; eNAD, exogenous NAD; ATP, Adenosine-5'-triphosphate; STP, staurosporine; AMP, Adenosine monophosphate; ADPr, adenosine 5'-diphosphoribose; NMN, Nicotinamide mononucleotide; NR, nicotinamide riboside; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; MPT, mitochondrial permeability transition; TMRE, Tetramethylrhodamine, ethyl ester, perchlorate; EX-25, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide

## Abstract

During the last several years, evidence that various enzymes hydrolyze NAD into bioactive products prompted scientists to revisit or design strategies able to increase intracellular availability of the dinucleotide. Yet, plasmamembrane permeability to NAD as well as mitochondrial origin of the dinucleotide still wait to be clearly defined. Here, we report that intracellular NAD contents increased upon exposure of cell lines or primary cultures to exogenous NAD (eNAD). NAD precursors could neither reproduce the effects of eNAD, nor they were found in the incubating media containing eNAD, thereby suggesting direct cellular eNAD uptake. Of note, we found that in mitochondria of cells exposed to eNAD, NAD and NADH as well as oxygen consumption and ATP production were increased. Conversely, DNA repair, a well-known NAD-dependent process, was unaltered upon eNAD exposure. We also report that eNAD conferred significant cytoprotection from apoptosis triggered by staurosporine, C2-ceramide or N-methyl-N'-nitro-N-nitrosoguanidine. In particular, eNAD reduced staurosporine-induced loss of mitochondrial membrane potential and ensuing caspase activation. Importantly, pharmacological inhibition or silencing of the NAD dependent enzyme SIRT-1 abrogated the ability of eNAD to provide protection from staurosporine, having no effect on eNAD-dependent protection from C2-ceramide or N-methyl-N'-nitro-N-nitrosoguanidine. Together, our findings on the one hand strengthen the hypothesis that eNAD crosses intact the plasmamembrane, and on the other provide evidence that increased NAD contents significantly affects mitochondrial bioenergetics and sensitivity to apoptosis.

## Introduction

During the last several years we witnessed to a renewed interest in the biochemistry and pharmacological potential of pyridine nucleotides NAD(H) and NADP(H). Rescued from the oblivion in which they were fallen because of the widespread view of their exclusive participation to redox metabolism, pyridine nucleotides are now known to be involved in pleiotypic cellular processes of key relevance to cell homeostasis and death (Koch-Nolte et al., 2009; Imai, 2009). Recent evidence that expression of NAD-synthesizing and -consuming enzymes, and the ensuing cellular NAD contents follow circadian rhythms (Nakahata et al., 2009) further emphasizes relevance of the dinucleotide to cell physiology.

NAD is now known to be a bona fide substrate of various enzymes involved in survival, death, signaling, inflammation and neoplastic transformation. Consequently, the pyridine nucleotide pool is not stable as previously envisaged, but highly dynamic, being continuously re-synthesized upon its hydrolysis operated by various NAD-consuming enzymes. This knowledge prompted strong interest in the biological properties of products originating from NAD hydrolysis, and also encouraged scientists of different fields to revisit the biochemistry of NAD neosynthesis from tryptophan, as well as NAD rescue from nicotinamide (Bogan and Brenner, 2008).

Poly(ADP-ribose) polymerases (PARPs) are proteins responsible for the majority of NAD consumption both under constitutive conditions and when hyperactivated by genotoxic stress (Rouleau *et al.*, 2010). Of note, basal activity of PARP-1 has been reported at complex DNA architectures such as hairpins or cruciform structures in the absence of DNA damage (Potaman et al., 2005). PARP-1-dependent poly(ADP-ribosyl)ation has been the focus of intense investigation because of its active role in DNA repair, inflammation and cell death. Potent PARP-1 inhibitors recently reached the clinical arena and are used in clinical trials for treatment of various types of solid neoplasms (Rouleau *et al.*, 2010). At variance with poly(ADP-ribosyl)ation, mono(ADP-ribose) transfer is less understood (Di Girolamo et al., 2005), and evidence is accumulating that putative PARPs are indeed enzymes able to exclusively catalyze mono-ADP-ribose transfer reactions (Hottiger et al., 2010). Additional NAD-consuming enzymes are sirtuins, a group of seven proteins (SIRT1-7) with various intracellular distribution able to catalyze the transfer of an acetyl group from

an acetylated protein to the ADP-ribose moiety of NAD with the formation of O-acetyl-ADP-ribose (Finkel et al., 2009). The NAD consumption potential of sirtuins is thought to be significantly lower than that of PARPs, even though sirtuins are emerging regulators of numerous cellular processes spanning from cell death to life-span elongation (Finkel et al., 2009). The ADP-ribosyl cyclases/NAD glycohydrolases CD38 and CD157 are supplementary NAD-consuming enzymes able to form ADP-ribose, cyclic-ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) (Malavasi et al., 2008). Although the first two compounds appear structurally similar, they are endowed with different functional properties, with ADP-ribose being able to bind the macro domain of proteins and also activate  $\text{Ca}^{2+}$ -permeable TRPM2 membrane receptors (Till and Ladurner, 2009; Perraud et al., 2001), and cyclic-ADP-ribose acting as an agonist of the endoplasmic reticulum  $\text{Ca}^{2+}$ -channel ryanodine receptor (Guse et al., 1999). NAADP also regulates intracellular calcium release (Koch-Nolte et al., 2009).

Ongoing intracellular NAD consumption allows to hypothesize that under basal or stressful conditions the dinucleotide content may become limiting in specific cell compartments. Addressing this issue is of remarkable relevance to cell biology because would identify an unprecedented regulatory step of different metabolic pathways. In addition, limiting NAD concentrations would also be a pharmacological target of potential therapeutic significance. Compounds able to boost or reduce NAD contents, indeed, might be original tools to pharmacologically modulate specific cellular functions (Belenky et al., 2007; Sauve, 2008). Metabolic NAD precursors have been classically used to increase its intracellular contents and, recently, also to boost the activities of the NAD-dependent enzymes. However, it is still debated whether NAD per se can cross the plasmamembrane. Although the canonical view considers NAD unable to permeates lipid bilayers (Di Lisa and Ziegler, 2001), several studies report evidence for exogenous NAD (eNAD) uptake by different cells (Bruzzone et al., 2001; Ying et al., 2003; Alano et al., 2004; Araki et al., 2004; Pillai et al., 2005; Qin et al., 2006; Billington et al., 2008; Wang et al., 2008; Alano et al., 2010). In the present study, we further investigated cellular uptake of eNAD, and also focused on its possible functional effects as indirect evidence of eNAD entrance.

## Materials and Methods

### Cell culture conditions, transfection, death assay, ROS production

HeLa, RAW and HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2mM glutamine, 10% fetal bovine serum and antibiotics. Cultures were brought to 50-70% confluence and used for the experiments. Pure neuronal cultures were prepared by seeding cortical cells obtained from 16 days old rat embryos as previously described (Chiarugi, 2002). Neurons were cultured in Neurobasal™ medium with B-27 supplement (GIBCO) and 0,5 mM glutamine onto poly-D-lysine-coated multiwell plates. Cells were used after 7 and 15 days in vitro (DIV) from preparation. Rat glia cultures were prepared as described (Chiarugi and Moskowitz, 2003) and used at 15 DIV. Cell cultures were exposed to NAD, ADPR, Nam, NMN, NR, AMP, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), C2-ceramide, staurosporine (STP), H<sub>2</sub>O<sub>2</sub>, EX-257 (6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide), or other compounds directly dissolved in the culture media. Nicotinamide riboside (NR) was synthesized as described by Yang et al. (Yang et al., 2007b). Cell transfection was performed as described (Cipriani et al., 2005) by using siRNA for SIRT1 from QIAGEN (Milan, Italy). Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay and phase-contrast microscopy (Cipriani et al., 2005). Caspase 3 activity was evaluated by means of a fluorimetric kit (Molecular Probes, Eugene, OR). An inverted Nikon TE-2000U microscope equipped with a CDD camera was used for cell visualization. ROS have been quantified by means of the dichloro-fluorescein assay.

### NAD, NADH and ATP measurement

NAD(H) contents were quantified by means of an enzymatic cycling procedure according to Cipriani et al (Cipriani et al., 2005). Briefly, cells grown in a 48 well plate were killed with 50 µl HClO<sub>4</sub> 1N and then neutralized with an equal volume of KOH 1N for NAD measurement, whereas the opposite was done for NADH extraction with an additional heating (60°C/30') between KOH and HClO<sub>4</sub>. After the addition of 100 µl of bicine 100 mM pH 8, 50 µl of the cell extract was mixed with an equal volume of the bicine buffer containing 23 µl/ml ethanol, 0.17 mg/ml MTT, 0.57 mg/ml phenazine ethosulfate and 10 µg alcohol dehydrogenase. Mixture was kept at room temperature

for 20' and then absorbance a 550 nm was measured. The amount of NAD consumed upon exposure to H<sub>2</sub>O<sub>2</sub> was calculated by subtracting the amount of NAD measured in cells at various time points after H<sub>2</sub>O<sub>2</sub> challenge to that present in control cells. A standard curve allowed quantification of NAD. Intracellular NADH content were evaluated by analysing cell autofluorescence as previously reported (Cipriani et al., 2005). Briefly, autofluorescence was visualized or measured with a microscopic apparatus (Nikon 2000-TE) equipped with an UV filter (ex. 365 nm) and a CCD camera or spectrometer. The cellular ATP content and mitochondrial ATP production was measured by means of ATPlite kit from Perkin Elmer (Belgium) as described (Cipriani et al., 2005).

### **Mitochondrial isolation and membrane potential analysis**

Mitochondria were isolated from cells using a glass/glass homogenizer in 500 µl of extraction buffer and centrifuged at 600 g as described (Formentini et al., 2009). Briefly, supernatants were centrifuged at 7000 g to obtain the mitochondrial pellet which was denatured with perchloric acid for NAD content determination. Mitochondrial membrane potential ( $\Delta\Psi_m$ ) was evaluated by means of a spectrofluorometer (Victor<sup>3</sup>, Perkin Elmer, Milan, Italy). Briefly, TMRE fluorescence was quantitated in cells grown in a 48 well plate, exposed or not to staurosporine 300 nM in the presence or absence of NAD for 2 and 6 hrs. TMRE was added to the culture media at 2.5 nM 30 min before fluorescence determination.

### **Western blotting**

For Western blotting, cells were scraped, collected in eppendorf tubes, centrifuged (1500 g/5 min/4°C) and resuspended in lysis buffer [50 mM Tris pH 7.4, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 4 µg/ml aprotinin and leupeptin, 1% SDS]. 20-40 µg of protein/lane were loaded. After 4-20% SDS-PAGE and blotting, membranes (Immobilon-P Millipore, Bedford, MA) were blocked with phosphate buffered saline (PBS) containing 0.1% Tween-20 and 5% skimmed milk (TPBS/5% milk) and then probed overnight with primary antibodies (1:1000 in TPBS/5% milk). The anti-PAR monoclonal antibody (10H) was from Alexis (Vinci, Italy). Membranes

were then washed with TPBS and incubated 1 h in TPBS/5% milk containing an anti mouse peroxidase-conjugated secondary antibody (1:2000). After washing in TPBS, ECL (Amersham, UK) was used to visualize the peroxidase-coated bands.

### **PCR assays**

One  $\mu\text{g}$  of total RNA isolated from treated or untreated cells was retro-transcribed using iScript™ kit (Bio-Rad, Hercules, USA) and amplified with the following specific primers: SIRT1: Forward 5'-GAACAGGTTGCGGGAATCC-3' and Reverse 5'-CAAGCGGTTTCATCAGCTGG-3'; 18S ribosomal RNA: Forward 5'-CGGCTACCACATCCAAGGAA-3' and Reverse 5'-GCTGGAATTACCGCGGCT-3'. Real-time PCR assays were performed by Rotor-Gene™ SYBR® Green PCR Kit (Qiagen, Milan, Germany) and analyzed using the Rotor-Gene 3000 cycler system (Corbett Research, Mortlake, Australia). Semiquantitative PCR was performed as described (Formentini et al., 2009). For semi-quantitative PCR the protocol described by Formentini et al. (Formentini et al., 2009) was adopted using the primers described above.

### **Mitochondrial and cytosolic ATP measurement**

ATP was indirectly quantified by means of cytosol- or mitochondria- targeted luciferase. Transfection with cytLuc or mitLuc cDNA (4  $\mu\text{g}/\text{ml}$ ) was performed by the standard calcium-phosphate procedure. Cell luminescence was evaluated 36h after transfection by means of a luminometer. As previously reported, recordings did not exceed 15 min because longer measurements may be biased by factors other than intracellular ATP such as Coenzyme A or luciferin availability, pH as well as oxyluciferin and oxygen radicals formation.

### **Comet assay**

DNA strand breaks were evaluated by the comet assay. Cells were treated or not with 100  $\mu\text{M}$   $\text{H}_2\text{O}_2$  in PBS on ice for 5 min. Later on cells were trypsinized whereas those used for evaluation of DNA repair were incubated for a further 2 hrs at 37°C after substitution of the  $\text{H}_2\text{O}_2$  solution with fresh culture medium, and then run through the comet assay. Briefly, after trypsinization cells were



centrifuged and then resuspended in low melting point agarose and layered on microscopy slides to be run through the comet assay. Microscopic analysis was carried out using a Labophot-2 microscope (Nikon, Japan) provided with epifluorescence. Each experimental point was run in duplicate and the images of 50 randomly chosen nuclei per slide were captured and analysed using the Comet Assay IV image analysis system (Perceptive Instruments, UK). The program calculated the total fluorescence of each nucleus and the fluorescence distribution of the head and tail of the comet. Data were expressed as percent of total fluorescence migrated in the tail for each nucleus (% DNA in tail), a parameter linearly related to the number of DNA breaks. The mean % DNA in tail of 50 nuclei per slide was calculated, and the duplicate values were further averaged. The value of % DNA in tail obtained estimated the basal and induced DNA damage in terms of strand breaks.

### **Oxygen consumption analysis**

Quantitation of oxygen consumption by cells exposed or not to NAD for 6 h was conducted by means of the Oxygraph system (Hansatech Instruments, Norfolk, UK). Cells (250,000) were loaded in the chamber in 400  $\mu$ l of respiration buffer (70 mM sucrose, 220 mM mannitol, 2 mM HEPES pH 7.4, 5 mM  $MgCl_2$ , 5 mM  $K_2HPO_4$ , 1 mM EDTA, 0.1% BSA) and oxygen consumption monitored for 10 min at 37°C.

### **NAD precursor quantitation by LC-MS/MS**

Growth media were replaced with PBS and cells exposed to NAD 1 mM/1 h directly dissolved in the solution. After 1 h, the culture medium was extracted with methanol for protein precipitation, centrifuged at 14,000 rpm for 15 min, lyophilized and then resuspended in 100  $\mu$ l of water 3%  $CH_3CN$ . Five  $\mu$ l of the solution were injected into a HPLC Perkin Elmer Series 200 micro pump apparatus and chromatographed using a 50x2.1 mm i.d. 3.5  $\mu$ m particle size 200 Å ZIC-HILIC (SeQuant) column. Mobile phase A consisted of water containing 3%  $CH_3CN$  and 10 mM AmAc, and mobile phase B was  $CH_3CN$  containing 3% water and 10 mM AmAc. An elution gradient was

performed going from 100 to 40% B in 20 min; B was held at 40% for 7 min, and then brought back to the starting value in 1 min. The equilibration time before the next injection was 10 min. The eluate, at a flow rate of 200  $\mu\text{l}/\text{min}$ , was directly introduced into the LC/MS interface. The LC-MS/MS system consisted of a Perkin Elmer Sciex (Thornhill, Canada) API 365 triple quadrupole mass spectrometry equipped with a Turbo IonSpray Interface. The compounds were ionized by positive ion electrospray and detected using multiple reaction monitoring (MRM). The needle and orifice voltage were adjusted to 6.0 kV and 61V, respectively. The drying gas flow rate and temperature were  $7\text{Lmin}^{-1}$  and  $250^\circ\text{C}$ , respectively. The first and third quadrupole mass analyzers were operated at unit mass resolution. Fragmentation was accomplished with a collision energy of 40 eV; nitrogen was used as the collision gas at a collision gas thickness (CGT) of  $2.6 \times 10^{15}$  molecules  $\text{cm}^{-2}$ . The ion transitions monitored were  $m/z$  123.0  $\rightarrow$  79.9 for nicotinamide, 335.1  $\rightarrow$  123.1 for NMN, 348.1  $\rightarrow$  135.9 for AMP, 560.0  $\rightarrow$  349 for ADPr and 664.0  $\rightarrow$  428.2 for NAD. These transitions were selected based on the triple quadrupole Collision-induced dissociation (CID) product ion spectrum of the analyte.

## Results

### eNAD is transported intact across the plasmamembrane

We first attempted to investigate whether eNAD can cross the plasmamembrane and increases intracellular NAD (iNAD) content. Cells were incubated in the growth medium and the nucleotide dissolved in saline directly added to the medium itself. As shown in Fig. 1A, exposure of HeLa cells to different concentrations of eNAD led to significant increases of iNAD. Specifically,  $1\mu\text{M}$  eNAD did not increase the cellular pool even after prolonged incubation times. When eNAD was raised up to  $10\mu\text{M}$ , a tendency to increase of iNAD contents was noted after 6 h. Exposure to  $100\mu\text{M}$  or  $1\text{mM}$  concentrations caused significant increases of iNAD ( $221 \pm 18$  and  $342 \pm 28$  % after 6 h, respectively). Notably, iNAD contents were not increased when cells exposure to  $1\text{mM}$  eNAD was conducted at  $4^\circ\text{C}$  (Fig.1A). When cultures of mouse macrophages (RAW242 cells), human hepatoma cells (HepG2) or rat primary astrocytes were exposed to  $1\text{mM}$  eNAD for 6 h, iNAD increments were also obtained (Fig. 1B). Interestingly, iNAD increased in cortical neurons exposed

to 1mM eNAD only in cultures of 15 days in vitro (DIV) whereas was ineffective in cultured of 7 DIV (Fig. 1B).

Although previous findings demonstrate that iNAD contents increase upon exposure to eNAD, they do not prove that eNAD crosses the plasmamembrane intact. In principle, eNAD might be hydrolyzed into cell permeable metabolites that, once have crossed the plasmamembrane, reform NAD through the rescue pathway. To address this issue, we exposed HeLa cells to different NAD precursors alone or in combination, at concentrations identical to that of eNAD (1mM), and measured their effects on iNAD contents. We reasoned that eNAD could be hydrolyzed by phosphodiesterases/pyrophosphatases into AMP and nicotinamide mononucleotide (NMN), or by NADases/NAD glycohydrolases into ADP-ribose and nicotinamide. The possibility that NMN could undergo dephosphorylation by membrane nucleotidases forming nicotinamide riboside was also taken into account. We found that, as expected, nicotinamide, nicotinamide riboside and NMN exposure augmented iNAD, although to an extent several fold lower than that prompted by NAD. Interestingly, ADP-ribose reduced both basal NAD contents and those increased by nicotinamide, whereas AMP had no effect (Fig. 1C). These findings are at odds with the hypothesis that eNAD increase iNAD contents because of extracellularly-formed NAD precursors. To corroborate this assumption, by means of LC/MS we also checked whether these NAD derivatives were present in the medium of cells exposed to eNAD. We optimized the analytical method to reach a sensitivity threshold of 5.3, 1.16, 1.15, 3.6, 2.18 ng for ADP-ribose, AMP, nicotinamide, NMN and nicotinamide riboside, respectively. Under our experimental settings, despite cells were incubated for 2 or 6 hrs in 1 ml of incubating solution (PBS added with 5 mM glucose and 10% fetal bovine serum) containing 1mM NAD (corresponding to 666  $\mu$ g of NAD), none of the above-mentioned NAD-metabolites was found in the incubating medium (not shown). Together, these findings suggested that eNAD permeates intact the plasmamembrane. Finally, we analyzed the effect of eNAD on iNAD depletion induced by FK866, a nicotinamide phosphoribosyltransferase (Nampt) inhibitor. We found that the effect of FK866 [used at 100 $\mu$ M to prompt rapid depletion of iNAD (Pittelli *et al.*, 2010)] was completely abolished in the presence of eNAD (Fig. 1D).

### Mitochondria sense eNAD

Mitochondria contain conspicuous amounts of intracellular NAD, although the contents vary according to the different cell type (Alano *et al.*, 2007). It is also accepted that the internal membrane of the organelle is impermeable to pyridine nucleotide, thereby leaving unanswered the key question of the origin of mitochondrial NAD. Another question of central relevance to cellular homeostasis that still waits to be answered is whether mitochondrial NAD(H) content is limiting the enzymatic reactions that utilize the nucleotide within the matrix, including the Krebs cycle. To our knowledge, whether eNAD alters mitochondrial bioenergetics has not been investigated. Remarkably, we found that eNAD was able to increase the mitochondrial content from  $3.1 \pm 0.2$  to  $7.3 \pm 0.7$  nmol/mg prot, whereas nucleocytosolic increments were more contained, raising from  $1.3 \pm 0.3$  to  $2.3 \pm 0.2$  nmol/mg prot (Fig. 2A). Considering that the Krebs cycle rapidly converts NAD into NADH, we then evaluated the cellular content of the latter. Fig. 2B shows that NADH levels were also increased in eNAD exposed cells. Accordingly, cell autofluorescence, a classic index of reduced pyridine dinucleotide contents (Cipriani *et al.*, 2005), increased in cells exposed to eNAD. As shown in Fig. 2C, autofluorescence was present in round- and rod-shaped bodies scattered throughout the cytoplasm showing the prototypical mitochondrial morphology. Notably, mitochondrial autofluorescence substantially increased in HeLa cells exposed to 1mM NAD for 6 h (Fig. 2C). Acquisition of the autofluorescence emission spectrum obtained by means of a 356 nm excitation filter gave a peak of 450 nm which is typical of NAD(P)H, further suggesting that the increase of fluorescence intensity in cells exposed to eNAD is due to reduced pyridine dinucleotide accumulation (Fig. 2D). Concomitant mitochondrial increase of NAD and NAD(P)H in eNAD exposed cells rules out the possibility that increased NADH content in the organelles is due to cytosolic transfer of reducing equivalents through the mitochondrial malate-aspartate shuttle. Given that cytosolic NAD is essential for glycolysis, and NADH plays a key role in mitochondrial bioenergetics by donating electrons to respiratory complex I, we next investigated whether eNAD affects cellular energy production. ATP contents readily increased in cells exposed to 1mM NAD for 1-6h (FIG. 2E). To ascertain whether the increase of ATP was due to mitochondrial production, we starved cells overnight in the absence of glucose and in the presence of the mitochondrial

energy substrates glutamine and pyruvate. Under these experimental conditions, eNAD was still able to increase cellular ATP contents (Fig. 2F), suggesting that mitochondria contribute to the eNAD-dependent ATP increase. Furthermore, given that ATP increase at 1 h did not differ in the absence or presence of glucose ( $4.9\pm 1.1$  and  $4.8\pm 0.7$  nmol ATP/mg prot, respectively, Fig. 2F), data suggested that mitochondria were mainly responsible for eNAD-dependent increased energy production. To substantiate this assumption, we next transfected HeLa cells with cytosolic or mitochondrial luciferase, a strategy allowing to discriminate ATP production in the two cell compartments. As shown in Fig. 2G, eNAD-dependent increase of ATP production not only occurred in the cytosol but also in the mitochondria. Further confirmation of the increased metabolic activity of mitochondria of eNAD-exposed cells, we found that oxygen consumption was higher in cells exposed 6h to 1 mM eNAD (Fig. 3A and B). However, despite the increased respiratory activity, eNAD did not increase reactive oxygen species formation (Fig. 3C). As a whole, these findings suggest that eNAD reaches the mitochondrial matrix and boosts oxidative phosphorylation and ATP production upon conversion into NADH. In this regard, it is worth noting that the increased availability of ATP might promote NMNAT activity that, in turn, contributes to the increased iNAD contents.

### **eNAD does not improve DNA repair**

Because of the key role of PARP-1 in single and double DNA strand break repair, and the large consumption of NAD attributed to the enzyme during genotoxic stress (Rouleau *et al.*, 2010), we wondered whether eNAD exposure could promote PARP-1-dependent DNA repair. HeLa cells were exposed to H<sub>2</sub>O<sub>2</sub>, a prototypical PARP-1 activator leading to activation of the base excision repair (BER) apparatus. A large body of evidence demonstrates that PARP-1 activity is instrumental for proper assembly and function of the BER machinery (Fisher *et al.*, 2007). We first wondered whether the kinetics of PARP-1-dependent NAD depletion differed between control or eNAD-exposed cells. As evidenced by the increased PAR content, the challenge of HeLa cells with H<sub>2</sub>O<sub>2</sub> led to significant increase of PARP-1 activity (Fig. 4A). Interestingly, we found that, upon H<sub>2</sub>O<sub>2</sub> exposure, the amount of NAD consumed by PARP-1 was higher in eNAD-challenged cells,

suggesting that nuclear NAD is limiting PARP-1 activity, at least under these experimental conditions (Fig. 4B).

Next, to understand whether the increased synthesis of poly(ADP-ribose) (PAR) had a functional correlate, we analyzed DNA repair in control and eNAD-exposed cells. By means of the COMET assay, we first determined the lower concentrations of H<sub>2</sub>O<sub>2</sub> able to induce an extent of DNA damage that could be repaired within a reasonable short period of time. As shown in Fig. 4C, 100 μM H<sub>2</sub>O<sub>2</sub> caused a damage that could be significantly repaired within 2 h. Notably, DNA repair did not differ in control or eNAD-exposed cells (1mM/6h) (Fig. 4C and D).

### **Effects of eNAD on apoptotic cell death**

Because of the key role of NAD-consuming enzymes such as PARP-1 or SIRT1 in apoptotic cell death, as well as the bioenergetic status of mitochondria in activation of the apoptotic machinery, we next wondered whether eNAD exposure could affect this type of cell demise. To this end, we exposed cells to three different apoptotic triggers such as staurosporine, C2-ceramide and MNNG. Staurosporine is a potent, non specific protein kinase inhibitor prompting a type II apoptosis, C2-ceramide also activates mitochondria-dependent apoptosis through unknown mechanisms, whereas MNNG activates a caspase-independent apoptotic program mainly due to mitochondrial apoptosis inducing factor (AIF) release. MNNG is an alkylating agent typically used to prompt PARP-1-dependent apoptosis (Cipriani et al., 2005). Remarkably, we found that eNAD exposure reduced cell death triggered by the three cytotoxic chemicals (Fig. 5A-C). Specifically, the effects of eNAD on staurosporine-dependent cell death was significant at concentrations of 100 μM, and further increased at 1 mM (Fig. 5C). Notably, the cell death assay we used (MTT reduction) is based on dye reduction by respiratory Complex IV, therefore measuring electron transfer from succinate to cytochrome oxidase (Berridge and Tan, 1993) that could be biased by the increased iNAD concentrations. However, as shown in Fig. 5C, we found that MTT reduction did not differ in cells exposed 24 h to eNAD compared to control ones. One possible explanation is that the increased mitochondrial NAD availability boosts the Krebs cycle without reaching the SHD step, or that increased mitochondrial NAD selectively promotes the activity of pyruvate dehydrogenase or

additional NAD-dependent enzymes of the Krebs cycle which have a different  $K_m$  for NAD. Regardless, we also evaluated eNAD-cytoprotection by phase contrast microscopy. Fig. 5D shows that at 100  $\mu$ M and 1 mM eNAD reduced apoptotic appearance of adherent cells, which appeared healthy, with diminished nuclear condensation. Given the ability of eNAD to increase iNAD content, we wondered whether cytoprotection could be, at least in part, mediated by prevention of NAD depletion induced by the cell stressor. We found that, NAD did not decrease up to 6 h in cells exposed to C2-ceramide or staurosporine (not shown). Conversely, MNNG induced a robust NAD depletion in control cells. Notably, cells exposed to MNNG and preincubated with eNAD had NAD levels that were almost twice those of control cells (Fig. 5E), an event that can well underlie eNAD-dependent protection from MNNG.

Next we attempted to investigate the mechanisms responsible for eNAD-dependent protection from C2-ceramide or staurosporine. We first focused on mitochondria because of their active role in apoptosis and the ability of eNAD to improve their bioenergetics. A key event in activation of the intrinsic apoptotic route is mitochondrial permeability transition (MPT) due to opening of the permeability transition pore (PTP), an event regulated by pyridine nucleotide content and their redox status. Specifically, mitochondrial NADH reduces PTP opening, thereby protecting cells from apoptosis. Hence, to test whether MPT was affected by eNAD, we measured mitochondrial membrane potential in cells exposed for different times to staurosporine in the presence or absence of eNAD. Fig. 6A shows that mitochondrial membrane potential steeply decreased upon 2 and 6 h exposure to staurosporine to an extent similar to that induced by the protonophore FCCP. Of note, staurosporine-dependent depletion of mitochondrial membrane potential was in part prevented in those cells exposed to eNAD (1mM/6h). To gather further information that eNAD impaired activation of the intrinsic apoptotic pathway, we evaluated the dinucleotide effect on activity of caspase 3, a protein typically activated upon MPTP opening. Consistent with data on the effect of eNAD on staurosporine-dependent loss of mitochondrial membrane potential, we found that caspase activity was drastically reduced in cells exposed to staurosporine in the presence of eNAD (Fig. 6B). Notably, eNAD-dependent reduction of caspase 3 activation was more pronounced than the ability of the nucleotide to prevent loss of mitochondrial membrane potential.

These findings suggested that additional molecular mechanisms underpinned eNAD-dependent impairment of the apoptotic machinery.

We therefore reasoned that the antiapoptotic effect of eNAD could also be mediated by the increased availability of the dinucleotide to NAD-consuming enzymes. We ruled out that PARP-1 could be involved because inhibition, rather than activation, of the enzyme protects from apoptosis in general (Hong et al., 2004) and, specifically, from that induced by staurosporine (Simbulan-Rosenthal et al., 1999). Conversely, a key antiapoptotic role of SIRT1 emerged from numerous studies (Finkel *et al.*, 2009). We therefore investigated whether inhibition of SIRT1 affected eNAD-dependent protection from apoptosis. To this end, we exposed cells to eNAD and staurosporine in the absence or presence of the potent and selective SIRT1 inhibitor EX-257. Fig. 6C shows that the compound prevented the ability of eNAD to protect from staurosporine-induced apoptosis. Of note, EX-257 per se did not display any cytotoxic effect on resting cells. To rule out possible non specific effects underlying EX-257 cytoprotection, and to further underscore the relevance of SIRT1 to the antiapoptotic effects of eNAD, we silenced SIRT1 by means of siRNA. Upon 48 h exposure to siRNA, both quantitative and semiquantitative PCR demonstrated that SIRT1 transcript levels decreased to about 8% of control (Fig. 6D). We found that eNAD could not rescue SIRT1-silenced cells from staurosporine-induced apoptosis (Fig. 6E). However, neither inhibition nor silencing of SIRT1 affected eNAD-dependent protection from cell death induced by C2-ceramide or MNNG (not shown).

## Discussion

In the present study we report that exposure to eNAD substantially increases the dinucleotide cellular pool, suggesting plasmamembrane permeability. Notably, we also show that these increment takes place in different cellular compartments, and alters specific NAD-dependent reactions. As a whole, our findings indicate that some cellular functions are limited by pyridine nucleotide availability and can be pharmacologically enhanced by exposing cells to eNAD. In keeping with this hypothesis, a very recent study demonstrates that genetic or pharmacological



suppression of PARP-1 leads to increased availability of iNAD that is responsible for improved mitochondrial bioenergetics (Bai *et al.*, 2011).

Plasmamembrane permeability to pyridine nucleotides is controversial. It has been suggested that evidence for intracellular entrance of eNAD may be due to *i*) binding to the plastic of the plates, *ii*) binding to plasmamembrane without transport, and *iii*) extracellular hydrolysis followed by intracellular reconstitution. As for the latter possibility, we have been unable to detect NAD catabolites in the incubating media of cells exposed to eNAD, suggesting lack of extracellular NAD metabolism. Accordingly, none of the catabolites added alone or in combination to the culture media is able to reproduce the effect of eNAD. It might be possible, however, that degradation of eNAD below detection limit still produces metabolites able to enter the cell, such as nicotinamide riboside. Additional evidence that eNAD alters specific cellular functions indicates that it is bioactive and not inertly bound to plasmamembrane or other surfaces. Lastly, data showing that eNAD entrance is abrogated in cells incubated at 4°C rules out passive diffusion and suggests the involvement of specific transport mechanisms. This is in keeping with the finding that NAD enters neurons of 15 but not of 7 DIV, suggesting that expression of specific membrane proteins during *in vitro* neuronal differentiation is needed to uptake eNAD. In this regard, plasmamembrane transporters and/or channels involved in NAD uptake have been recently proposed (Billington *et al.*, 2008; Alano *et al.*, 2010).

The ability of eNAD to increase the mitochondrial NAD content and energy production is of particular relevance. At present, indeed, we still wait for a clear picture of the origin of mitochondrial NAD. Although fluxes of NAD through membranes of isolated mitochondria have been reported (Rustin *et al.*, 1997; Rustin *et al.*, 1996), it has been questioned whether membrane integrity is conserved during organelle isolation. Thus, the view that mitochondria are not permeable to pyridine nucleotides received large consensus. It is also not clear whether mitochondria have a functional NAD rescue pathway originating from nicotinamide or other precursors such as NMN or nicotinamide riboside (Berger *et al.*, 2005; Yang *et al.*, 2007a; Pittelli *et al.*, 2010). Regardless, the identification of membrane NAD transporters in yeast mitochondria (Todisco *et al.*, 2006) and intracellular vesicles of eukaryotic cells (Davis *et al.*, 2008), together with

the key biological relevance of the dinucleotide, mines the view that mammalian mitochondria lost this carrier and became impermeable to NAD. Our findings allow to speculate that either mitochondria uptake intact NAD directly from cytoplasm, or they uptake NAD precursors which are then transformed into NAD in the matrix. Although we cannot discriminate between these two possibilities, it is worth noting that the present study indicates that mitochondria sense cytoplasmic concentrations of NAD and/or its precursors, resetting their pyridine nucleotide pool accordingly. Also important is the notion that mitochondrial fluctuation of NAD contents according to those present in the cytoplasm does not seem bidirectional. Indeed, very recent work from our group reports that reduction of cytosolic NAD is not followed by concomitant reduction of NAD in mitochondria (Yang *et al.*, 2007a; Pittelli *et al.*, 2010). It seems, therefore, that these organelles are able to maintain their NAD content when that of cytosol decreases, but readily increase the pyridine nucleotide pool when the cytoplasmic availability of NAD and/or its precursors increases. Taken together, these findings suggest that mitochondria allow NAD resetting unidirectionally toward an increase, and not vice versa. Raising of mitochondrial NADH coupled with augmented ATP production in cells exposed to eNAD is a clear indication that increased concentrations of NAD in mitochondria are translated into improved bioenergetics. Data are also of relevance because indicate that mitochondrial NAD concentrations are limiting both the Krebs cycle and oxidative phosphorylation. In principle, this knowledge might have important implications in cell biology and treatment of mitochondrial dysfunction, such as those occurring in mitochondrial disorders, neurodegeneration, diabetes and aging. It is known, however, that almost complete (98% at 8 min) single-pass transformation of NAD infused into the portal vein or hepatic artery takes place in the perfused rat liver (Broetto-Biazon *et al.*, 2008), indicating rapid degradation by hepatocytes. Also, intracellular  $Ca^{2+}$  waves triggered by extracellular NAD degradation by CD38, can severely compromise cellular homeostasis.

Data showing that eNAD increases  $H_2O_2$ -induced PARP-1-dependent iNAD consumption but does not improve DNA repair suggest that not all NAD-dependent processes are limited by the intracellular dinucleotide concentrations. We interpret these findings considering that free nuclear NAD contents are limiting PARP-1 activity and PAR formation but not genome repair. This is in

keeping with evidence that *i*) intracellular pyridine nucleotide pool is mostly bound to proteins (Zhang et al., 2002), *ii*) proximity of the NAD producing enzyme NMNAT-1 to PARP-1 enhances poly(ADP-ribosyl)ation (Berger et al., 2007), and *iii*) eNAD increases DNA-damage-dependent PAR formation (Alano et al., 2010). On the other hand, our data hint that the amount of PAR produced with the physiological iNAD concentrations suffices to signal DNA repair. In apparent contrast with this hypothesis, eNAD improves efficiency of DNA repair in post-ischemic neurons in vitro (Wang et al., 2008). Although we cannot explain the reasons of this inconsistency, it is worth noting that the molecular mechanisms involved in OGD-induced DNA damage and repair differ qualitatively and quantitatively from those activated by H<sub>2</sub>O<sub>2</sub>. It is possible, therefore, that the ability of eNAD to assist DNA repair is stress- and cell type-dependent.

A key finding of our study is that apoptosis is reduced by increasing the extracellular concentrations of NAD. On the one hand, data underscore the functional effects of increased iNAD concentrations, and on the other provide important information on molecular mechanisms regulating the apoptotic machinery. Although several mechanisms could underpin eNAD cytoprotection, we report here that the dinucleotide reduces staurosporine-induced loss of mitochondrial membrane potential, a prototypical trigger of the intrinsic apoptotic pathway. Data are in keeping with prior work indicating a key role of pyridine nucleotides in regulating PTP opening (Halestrap et al., 2002). We also show that inhibition or silencing of the NAD-consuming, anti-apoptotic deacetylase SIRT1 abrogates eNAD-dependent cytoprotection from staurosporine but not from C2-ceramide or MNNG. Albeit at present the reason for such a specific role of SIRT1 is unclear, data are in keeping with the notion that staurosporine, C2-ceramide and MNNG prompt apoptosis through different mechanisms which, in turn, activate specific cell death pathways. In addition, as shown in Fig. 5E, eNAD may protect from MNNG-induced cell death by reducing iNAD depletion. Our data are consistent with previous reports showing that eNAD affords protection from various stresses such as beta-amyloid (Qin et al., 2006), ischemia (Wang et al., 2008), NMNAT inactivation (Wang et al., 2005) or PARP-1-dependent cell death (Pillai et al., 2005; Alano et al., 2010). The study by Pillai and colleagues showing that SIRT1 activity mediates the cytoprotective effects of eNAD addition in myocyte cell culture undergoing PARP-1 activation (Pillai

et al., 2005) further strengthens the link between eNAD availability and SIRT1-dependent protection from apoptosis. Likewise, recent work shows that increased iNAD availability due to PARP-1 inhibition promotes mitochondrial bioenergetics in a SIRT1-dependent manner (Bai *et al.*, 2011). Finally, evidence that eNAD post-treatment provides neuroprotection when PARP-1 inhibitors no longer have effects (Alano et al., 2010) underscores the therapeutic potential of pharmacological strategies increasing the dinucleotide extracellular contents.

In conclusion, the present study furthers our understanding of the biochemistry of NAD, underscoring its pharmacotherapeutic potential. Development of strategies able to increase the intracellular pool of NAD in specific cellular compartments may well represents a pharmacological challenge for the next future.

**Acknowledgments:** This study has been supported by grants from Federazione Italiana Sclerosi Multipla, Regione Toscana (Progetto Salute 2009) and Ente Cassa di Risparmio di Firenze.

#### **Author contribution**

Participated in research design: Pittelli, Giovannelli, Moroni, Chiarugi

Conducted experiments: Pittelli, Felici, Romano, Cialdai, Pitozzi, Bigagli

Performed data analysis: Pittelli

Wrote or contributed to the writing of the manuscript: Pittelli, Chiarugi

## Reference List

- Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM and Swanson RA (2010) NAD<sup>+</sup> Depletion Is Necessary and Sufficient for Poly(ADP-Ribose) Polymerase-1-Mediated Neuronal Death. *J Neurosci* **30**:2967-2978.
- Alano CC, Tran A, Tao R, Ying W, Karliner JS and Swanson RA (2007) Differences Among Cell Types in NAD(+) Compartmentalization: a Comparison of Neurons, Astrocytes, and Cardiac Myocytes. *J Neurosci Res* **85**:3378-3385.
- Alano CC, Ying W and Swanson RA (2004) Poly(ADP-Ribose) Polymerase-1-Mediated Cell Death in Astrocytes Requires NAD<sup>+</sup> Depletion and Mitochondrial Permeability Transition. *J Biol Chem* **279**:18895-18902.
- Araki T, Sasaki Y and Milbrandt J (2004) Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration. *Science* **305**:1010-1013.
- Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, Schoonjans K, Schreiber V, Sauve AA, Menissier-de Murcia J and Auwerx J (2011) PARP-1 Inhibition Increases Mitochondrial Metabolism Through SIRT1 Activation. *Cell Metab* **13**:461-468.
- Belenky P, Bogan KL and Brenner C (2007) NAD<sup>+</sup> Metabolism in Health and Disease. *Trends Biochem Sci* **32**:12-19.
- Berger F, Lau C, Dahlmann M and Ziegler M (2005) Subcellular Compartmentation and Differential Catalytic Properties of the Three Human Nicotinamide Mononucleotide Adenylyltransferase Isoforms. *J Biol Chem* **280**:36334-36341.
- Berger F, Lau C and Ziegler M (2007) Regulation of Poly(ADP-Ribose) Polymerase 1 Activity by the Phosphorylation State of the Nuclear NAD Biosynthetic Enzyme NMN Adenylyl Transferase 1. *Proc Natl Acad Sci* **104**:3765-3760.
- Berridge MV and Tan AS (1993) Characterization of the Cellular Reduction of 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT): Subcellular Localization, Substrate Dependence, and Involvement of Mitochondrial Electron Transport in MTT Reduction. *Arch Biochem Biophys* **303**:474-482.

- Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA, Canonico PL, Condorelli F and Genazzani AA (2008) Characterization of NAD Uptake in Mammalian Cells. *J Biol Chem* **283**:6367-6374.
- Bogan KL and Brenner C (2008) Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: a Molecular Evaluation of NAD<sup>+</sup> Precursor Vitamins in Human Nutrition. *Annu Rev Nutr* **28**:115-130.
- Broetto-Biazon AC, Bracht F, Sa-Nakanishi AB, Lopez CH, Constantin J, Kelmer-Bracht AM and Bracht A (2008) Transformation Products of Extracellular NAD(+) in the Rat Liver: Kinetics of Formation and Metabolic Action. *Mol Cell Biochem* **307**:41-50.
- Bruzzone S, Guida L, Zocchi E, Franco L and De Flora A (2001) Connexin 43 Hemi Channels Mediate Ca<sup>2+</sup>-Regulated Transmembrane NAD<sup>+</sup> Fluxes in Intact Cells. *FASEB J* **15**:10-12.
- Chiarugi A (2002) Characterization of the Molecular Events Following Impairment of NF-KappaB-Driven Transcription in Neurons. *Brain Res Mol Brain Res* **109**:179-188.
- Chiarugi A and Moskowitz MA (2003) Poly(ADP-Ribose) Polymerase-1 Activity Promotes NF-KappaB-Driven Transcription and Microglial Activation: Implication for Neurodegenerative Disorders. *J Neurochem* **85**:306-317.
- Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F and Chiarugi A (2005) Nuclear Poly(ADP-Ribose) Polymerase-1 Rapidly Triggers Mitochondrial Dysfunction. *J Biol Chem* **280**:17227-17234.
- Davis LC, Morgan AJ, Ruas M, Wong JL, Graeff RM, Poustka AJ, Lee HC, Wessel GM, Parrington J and Galione A (2008) Ca(2+) Signaling Occurs Via Second Messenger Release From Intraorganelle Synthesis Sites. *Curr Biol* **18**:1612-1618.
- Di Girolamo M, Dani N, Stilla A and Corda D (2005) Physiological Relevance of the Endogenous Mono(ADP-Ribosyl)ation of Cellular Proteins. *FEBS J* **272**:4565-4575.
- Di Lisa F and Ziegler M (2001) Pathophysiological Relevance of Mitochondria in NAD Metabolism. *FEBS Lett* **492**:4-8.
- Finkel T, Deng CX and Mostoslavsky R (2009) Recent Progress in the Biology and Physiology of Sirtuins. *Nature* **460**:587-591.

- Fisher AE, Hochegger H, Takeda S and Caldecott KW (2007) Poly(ADP-Ribose) Polymerase 1 Accelerates Single-Strand Break Repair in Concert With Poly(ADP-Ribose) Glycohydrolase. *Mol Cell Biol* **27**:5597-5605.
- Formentini L, Macchiarulo A, Cipriani G, Camaioni E, Rapizzi E, Pellicciari R, Moroni F and Chiarugi A (2009) Poly(ADP-Ribose) Catabolism Triggers AMP-Dependent Mitochondrial Energy Failure. *J Biol Chem* **284**:17668-17676.
- Guse AH, da Silva CP, Berg I, Skapenko AL, Weber K, Heyer P, Hohenegger M, Ashamu GA, Schulze-Koops H, Potter BV and Mayr GW (1999) Regulation of Calcium Signalling in T Lymphocytes by the Second Messenger Cyclic ADP-Ribose. *Nature* **398**:70-73.
- Halestrap AP, McStay GP and Clarke SJ (2002) The Permeability Transition Pore Complex: Another View. *Biochimie* **84**:153-166.
- Hong SJ, Dawson TM and Dawson VL (2004) Nuclear and Mitochondrial Conversations in Cell Death: PARP-1 and AIF Signaling. *Trends Pharmacol Sci* **25**:259-264.
- Hottiger MO, Hassa PO, Luscher B, Schuler H and Koch-Nolte F (2010) Toward a Unified Nomenclature for Mammalian ADP-Ribosyltransferases. *Trends Biochem Sci*.
- Imai S (2009) The NAD World: a New Systemic Regulatory Network for Metabolism and Aging-- Sirt1, Systemic NAD Biosynthesis, and Their Importance. *Cell Biochem Biophys* **53**:65-74.
- Koch-Nolte F, Haag F, Guse AH, Lund F and Ziegler M (2009) Emerging Roles of NAD<sup>+</sup> and Its Metabolites in Cell Signaling. *Sci Signal* **2**:mr1.
- Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T and Aydin S (2008) Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology. *Physiol Rev* **88**:841-886.
- Nakahata Y, Sahar S, Astarita G, Kaluzova M and Sassone-Corsi P (2009) Circadian Control of the NAD<sup>+</sup> Salvage Pathway by CLOCK-SIRT1. *Science* **324**:654-657.
- Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, Schmitz C, Stokes AJ, Zhu Q, Bessman MJ, Penner R, Kinet JP and Scharenberg AM (2001) ADP-Ribose Gating of the Calcium-Permeable LTRPC2 Channel Revealed by Nudix Motif Homology. *Nature* **411**:595-599.

- Pillai JB, Isbatan A, Imai S and Gupta MP (2005) Poly(ADP-Ribose) Polymerase-1-Dependent Cardiac Myocyte Cell Death During Heart Failure Is Mediated by NAD<sup>+</sup> Depletion and Reduced Sir2alpha Deacetylase Activity. *J Biol Chem* **280**:43121-43130.
- Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F and Chiarugi A (2010) Inhibition of Nicotinamide Phosphoribosyltransferase: Cellular Bioenergetics Reveals a Mitochondrial Insensitive NAD Pool. *J Biol Chem* **285**:34106-34114.
- Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL and Soldatenkov VA (2005) Specific Binding of Poly(ADP-Ribose) Polymerase-1 to Cruciform Hairpins. *J Mol Biol* **348**:609-615.
- Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA and Pasinetti GM (2006) Neuronal SIRT1 Activation As a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction. *J Biol Chem* **281**:21745-21754.
- Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG (2010) PARP Inhibition: PARP1 and Beyond. *Nat Rev Cancer* **10**:293-301.
- Rustin P, Chretien D, Parfait B, Rotig A and Munnich A (1997) Nicotinamide Adenine Dinucleotides Permeate Through Mitochondrial Membranes in Human Epstein-Barr Virus-Transformed Lymphocytes. *Mol Cell Biochem* **174**:115-119.
- Rustin P, Parfait B, Chretien D, Bourgeron T, Djouadi F, Bastin J, Rotig A and Munnich A (1996) Fluxes of Nicotinamide Adenine Dinucleotides Through Mitochondrial Membranes in Human Cultured Cells. *J Biol Chem* **271**:14785-14790.
- Sauve AA (2008) NAD<sup>+</sup> and Vitamin B3: From Metabolism to Therapies. *J Pharmacol Exp Ther* **324**:883-893.
- Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares H and Smulson ME (1999) Involvement of PARP and Poly(ADP-Ribosyl)ation in the Early Stages of Apoptosis and DNA Replication. *Mol Cell Biochem* **193**:137-148.



- Till S and Ladurner AG (2009) Sensing NAD Metabolites Through Macro Domains. *Front Biosci* **14**:3246-3258.
- Todisco S, Agrimi G, Castegna A and Palmieri F (2006) Identification of the Mitochondrial NAD<sup>+</sup> Transporter in *Saccharomyces Cerevisiae*. *J Biol Chem* **281**:1524-1531.
- Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW and He Z (2005) A Local Mechanism Mediates NAD-Dependent Protection of Axon Degeneration. *J Cell Biol* **170**:349-355.
- Wang S, Xing Z, Vosler PS, Yin H, Li W, Zhang F, Signore AP, Stetler RA, Gao Y and Chen J (2008) Cellular NAD Replenishment Confers Marked Neuroprotection Against Ischemic Cell Death: Role of Enhanced DNA Repair. *Stroke* **39**:2587-2595.
- Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, de Cabo R, Sauve AA and Sinclair DA (2007a) Nutrient-Sensitive Mitochondrial NAD<sup>+</sup> Levels Dictate Cell Survival. *Cell* **130**:1095-1107.
- Yang T, Chan NY and Sauve AA (2007b) Syntheses of Nicotinamide Riboside and Derivatives: Effective Agents for Increasing Nicotinamide Adenine Dinucleotide Concentrations in Mammalian Cells. *J Med Chem* **50**:6458-6461.
- Ying W, Garnier P and Swanson RA (2003) NAD<sup>+</sup> Repletion Prevents PARP-1-Induced Glycolytic Blockade and Cell Death in Cultured Mouse Astrocytes. *Biochem Biophys Res Commun* **308**:809-813.
- Zhang Q, Piston DW and Goodman RH (2002) Regulation of Corepressor Function by Nuclear NADH. *Science* **295**:1895-1897.

## Legends to Figures

### Figure 1. Effects of eNAD and metabolic precursors on iNAD contents in various cell lines.

(A) iNAD increase upon exposure of HeLa cells to eNAD is time, concentration and temperature dependent. (B) Increase of iNAD upon exposure of different cell lines (RAW mouse macrophages or C6 rat glioma cells) or primary astrocyte or neuronal cultures to 1mM NAD for 6 h. Neuronal cultures of 7 or 15 days in vitro (DIV) were used. (C) Effect of different NAD precursors added to the culture medium (1mM/6h) on iNAD content in HeLa cells. (D) Effect of 1 mM eNAD on iNAD depletion induced by FK866 (100  $\mu$ M/6h). In (A) each point represents the mean  $\pm$  s.e.m. of 4 experiments conducted in duplicate. In (B-D) each column represents the mean of 3 experiments conducted in duplicate. \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.001 vs control (i.e. w/o eNAD addition); ANOVA + Tukey's post hoc test. Nam (nicotinamide), NMN (nicotinamide adenine dinucleotide), NR (nicotinamide riboside); ADPR (ADP-ribose).

### Figure 2. eNAD affects mitochondrial bioenergetics of HeLa cells.

Effects of eNAD (1mM/6h) on nucleo-cytosolic and mitochondrial NAD content (A), or intracellular NADH levels (B). Rotenone (ROT, 10  $\mu$ M/1h) is used as positive control for NADH increase. (C) Effects of eNAD (1mM/6h) on cell autofluorescence. (D) Autofluorescence emission spectra of control or eNAD-exposed (1mM/6h) cells. (E) Effects of 1 mM eNAD on whole cell ATP contents. (F) ATP contents in cells exposed to 1mM eNAD for 30 or 60 min under control or glucose starvation (overnight) conditions. (G) Effects of eNAD (1mM/5h) on photon emission from cytosolic (Cyt-Lucif) or mitochondrial (Mit-Lucif) luciferase-transfected cells. Each column represents the mean  $\pm$  s.e.m. of at least 3 experiments. In images (C) or spectra (D) representative of 3 experiments are shown. \* $p$ <0.05, \*\* $p$ <0.01,  $P$ <0.001, vs control (A, B, E, F) or luciferase transfected cells (G). ANOVA + Tukey's post hoc test. Bar = 10  $\mu$ m.

### Figure 3. Effects of eNAD on oxygen consumption by HeLa cells.

(A) Representative experiment of the effects of eNAD (6h preincubation at 1 mM) on oxygen consumption. One experiment representative of six is shown. The arrow indicate the time when cells have been

added to the respiration buffer. (B) Oxygen consumption rate in control or eNAD exposed (6h preincubation at 1 mM) cells is shown. (C) ROS production in cells exposed to eNAD (1mM/6h) or to the Complex III inhibitor antimycin (100  $\mu$ M/2h, positive control). Each column represents the mean  $\pm$  s.e.m. of 6 (B) or 3 (C) experiments. \*\* $p$ <0.01, vs control. ANOVA + Tukey's post hoc test.

**Figure 4. effects of eNAD on H<sub>2</sub>O<sub>2</sub>-induced poly(ADP-ribosylation) and DNA repair.** (A) Western blotting of PAR content in control or H<sub>2</sub>O<sub>2</sub>-exposed cells (100  $\mu$ M/5 min). PAR appears as a smear because of the increased molecular weight of poly(ADP-ribosyl)ated proteins. (B) iNAD consumption in cells exposed to H<sub>2</sub>O<sub>2</sub> 100  $\mu$ M for different times and preincubated or not with eNAD 1mM/6h. The amount of NAD consumed upon exposure to H<sub>2</sub>O<sub>2</sub> was calculated by subtracting the amount of NAD measured in cells at various time points after H<sub>2</sub>O<sub>2</sub> challenge to that present in control cells. (C) Representative images of cell nuclei visualized with the comet assay of control cells, exposed for 5 min to H<sub>2</sub>O<sub>2</sub> 100  $\mu$ M or exposed to H<sub>2</sub>O<sub>2</sub> 100  $\mu$ M and then allowed to repair for additional 2 h without or with a 6 h preincubation to 1mM eNAD. (D) Measurement of DNA damage (% of DNA damage in tail) in cells treated as in (C). In (A) a blot representative of four is shown. In (B) each point represents the mean  $\pm$  s.e.m. of 3 experiments conducted in duplicate. In (D) each column represents the mean  $\pm$  s.e.m. of 3 experiments conducted in duplicate. \* $p$ <0.05, \*\* $p$ <0.01 vs control, # $p$ <0.05 vs H<sub>2</sub>O<sub>2</sub>. ANOVA + Tukey's post hoc test. Bar = 5  $\mu$ m.

**Figure 5. Effects of eNAD on apoptotic cell death.** Effects of exposure to the indicated concentrations of eNAD (6h) to cell death induced by C2-ceramide (A), MNNG (B) or staurosporine (C). (D) Phase contrast visualization of the effects of eNAD at the indicated concentrations on staurosporine (300 nM) induced cell death evaluated after an over-night incubation. (E) Effect of MNNG exposure (100  $\mu$ M/1h) on NAD content in control or eNAD- (1 mM/6h) exposed cells. In (A-C and E) each column represents the mean  $\pm$  s.e.m. of at least three experiments conducted in

duplicate. In (D) representative images of 3 experiments are shown. \* $p < 0.05$ , \*\* $p < 0.01$  vs the apoptotic inducer, # $p < 0.05$ , ## $p < 0.01$  vs Control. ANOVA + Tukey's post hoc test. Bar = 10  $\mu\text{m}$ .

**Figure 6. Mechanisms underlying the antiapoptotic effects of eNAD in HeLa cells.** (A) Effects of eNAD 1mM on reduction of mitochondrial membrane potential in cells exposed for 2 or 6 h to 300 nM staurosporine. The protonophore FCCP (1 $\mu\text{M}$ ) was used as a positive control of mitochondrial membrane depolarization. (B) Effects of eNAD 1mM on staurosporine (STP, 300 nM/6h)-induced caspase activation. (C) Effects of the SIRT1 inhibitor EX-257 on eNAD-dependent staurosporine (STP, 300 nM/overnight)-induced cell death. eNAD was incubated at the concentration of 1mM. (D) Real time (a) and semiquantitative (b) PCR evaluation of SIRT1 transcript levels in control and silenced cells. 18 S ribosomal RNA is shown as a loading control. (E) Lost of protection from staurosporine-induced apoptosis by eNAD in SIRT1-silenced cells. Cells were exposed to 1 mM eNAD and challenged with 300 nM staurosporine overnight. Each column represents the mean  $\pm$  s.e.m. of at least three experiments conducted in duplicate. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  vs control (B, E) or staurosporine (A, C); # $p < 0.05$  vs STP; ANOVA + Tukey's post hoc test .




Figure 1




Figure 2






Figure 3




Figure 4






Figure 5




Figure 6